Nasal delivery device platforms for drug, biologics, and botanicals
Zeteo Biomedical offers ZTech-L™ for liquids and ZTech-P™ for dry powders, providing versatile nasal delivery platforms for various actives. The devices support single-use and multi-dose formats, ensuring precise dosing and ease of use across age groups. TRL 6.
Overview
Zeteo Biomedical presents two innovative nasal delivery platforms: ZTech-L™ for liquid formulations and ZTech-P™ for dry powders. These platforms are designed to provide precise dosing, portability, and ease of self-administration, catering to all age groups. They feature unit-dose packaging that maintains the shelf life and potency of the active ingredients without the use of preservatives. The compatibility with a wide range of actives, including small molecules, biologics, GRAS botanicals, and microbiome-targeted agents, makes these devices suitable for both OTC and regulated applications.
Technical specifications
- Device Formats: Available in single-use and multi-dose formats.
- Design: Ergonomic and patient-centric for easy self-administration.
- Preservation: Unit-dose packaging to ensure stability and potency without preservatives.
- Compatibility: Supports a broad spectrum of actives, including small molecules, biologics, and botanicals.
- Evaluation: Extensively tested through analytical testing and preclinical studies, confirming safety and reliable performance.
Technology readiness level
The ZTech-L™ and ZTech-P™ platforms are at Technology Readiness Level 6, having been validated through comprehensive preclinical testing and analytical evaluations. They are ready to support rapid development and commercialization of OTC nasal combination products.
About Zeteo Biomedical LLC
Zeteo Biomedical LLC develops and commercializes advanced, patient-centric drug and biologic delivery systems, specializing in needle-free technology for pharmaceutical, biotech, and personal care applications. The company’s core offerings, the ZTECH-L and ZTECH-P platforms, support the administration of liquid, powder, and reconstituted formulations via ophthalmic, intranasal, nose-to-brain, and sublingual routes. These devices are designed for precision dosing, portability, and ease of use, featuring innovations that allow for reliable functionality in various physical orientations, including microgravity environments. The company complements its proprietary hardware with a suite of technical services, including device prototyping, analytical testing, process engineering, and support for clinical and commercial supply chain management.
By focusing on compact and intuitive design, Zeteo helps its partners improve patient adherence and medical outcomes for conditions ranging from neurodegenerative disorders and pain management to infectious diseases. The company plays a significant role in public health initiatives, having joined the Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) consortium to expedite the distribution of vaccines and biomedical countermeasures. With a robust international patent portfolio, Zeteo provides end-to-end support for drug-device combination products, aiming to maximize treatment efficacy while minimizing drug waste and environmental impact. Their services assist partners from early-stage development through to commercial-scale production and technology licensing.
delivered to your inbox.